LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the drug pipeline for the atypical hemolytic uremic syndrome. The report includes a detailed analysis of the ...

Please provide your email address to receive an email when new articles are posted on . The FDA today granted fast track status to OMS721 — a complement inhibitor — for the treatment of patients with ...

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Atypical Hemolytic Uremic Syndrome pipeline constitutes 5+ key companies continuously working towards developing 5+ ...

LONDON, United Kingdom — For patients with atypical hemolytic uremic syndrome (HUS), the improvement in estimated glomerular filtration rate (eGFR) is significantly better when eculizumab (Soliris, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Atypical hemolytic uremic syndrome is a ...

- At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response - Atypical HUS affects both adults and children and many ...

The management of patients with hemolytic uremic syndrome is challenging, and strategies for accurate diagnosis and effective treatment are needed. Intensive research over the past several years has ...

Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels ...

The US Food and Drug Administration (FDA) has approved ravulizumab (Ultomiris, Alexion Pharmaceuticals) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and children age 1 ...

ORLANDO, Fla.--(BUSINESS WIRE)--The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced ...